Holen Sie sich die Stockscreener-App
35.75
2.14%
0.75
Handel nachbörslich:
36.46
0.71
+1.99%
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Citizens reiterates Crinetics stock rating on strong launch data By Investing.com - Investing.com Canada
CRNX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $81 - GuruFocus
H.C. Wainwright reiterates Crinetics stock rating on durability data By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Crinetics (CRNX) Reveals Promising Long-Term Results for Palsoni - GuruFocus
In CAH trial, daily pill cut steroid doses as hormone levels fell - Stock Titan
Crinetics shows Phase 2 success for atumelnant in reducing hormones and glucocorticoid use in CAH patients - Pluang
Crinetics (CRNX) Shares New Phase 2 Study Results on Atumelnant - GuruFocus
Crinetics presents phase 2 data for CAH treatment atumelnant By Investing.com - Investing.com South Africa
Crinetics Presents Full Results From Phase 2 Trial of - GlobeNewswire
Crinetics Pharmaceuticals Presents Long-Term Efficacy and Safety Data for PALSONIFY at ENDO 2026 - Quiver Quantitative
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control - GlobeNewswire Inc.
Sector Gamma AS Makes New $5.35 Million Investment in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX) reports Q1 loss, beats revenue estimates - MSN
Positive Outlook for Crinetics (CRNX) After Camurus' Regulatory Setback - GuruFocus
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for - MSN
CRNX Reiterated by Citizens -- Price Target Maintained at $95 - GuruFocus
Citizens reiterates Crinetics stock rating on Palsonify launch strength - Investing.com UK
Crinetics Pharmaceuticals' (CRNX) Market Outperform Rating Reaffirmed at Citizens Jmp - MarketBeat
Citizens reiterates Crinetics stock rating on Palsonify launch strength By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why - Insider Monkey
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by GW&K Investment Management LLC - MarketBeat
Crinetics' Everyday Advocacy initiative to support Cushing's care - Cushing's Disease News
WINTON GROUP Ltd Sells 39,816 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Understanding the Setup: (CRNX) and Scalable Risk - Stock Traders Daily
Geode Capital Management LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026 - Yahoo Finance
Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics - Barchart.com
Crinetics Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - marketscreener.com
Crinetics launches patient education program for endocrine diseases - Investing.com UK
Crinetics launches patient education program for endocrine diseases By Investing.com - Investing.com Australia
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities - The Manila Times
New Everyday Advocacy tools help endocrine patients navigate care - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
Crinetics Pharmaceuticals Highlights Positive Clinical Data for PALSONIFY™ and Atumelnant at ENDO 2026 Conference - Quiver Quantitative
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - The Manila Times
What Do Analysts Say About Crinetics Pharmaceuticals (CRNX)? - Insider Monkey
5 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
The Technical Signals Behind (CRNX) That Institutions Follow - Stock Traders Daily
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 - The Manila Times
Crinetics management to meet investors at Jefferies healthcare event - Stock Titan
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? - AOL.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Precision Trading with Crinetics Pharmaceuticals Inc. (CRNX) Risk Zones - Stock Traders Daily
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):